Halneuron tetrodotoxin
Chemotherapy-induced neuropathic pain Persistent painful peripheral neuropathy after chemotherapy · painful CIPN
An assessment of this drug’s estimated clinical-trial progression, ahead of its next catalyst.
Pain efficacy and safety readout · sponsor timing guidance
Gosset PTRS learns from historical clinical trials and uses the trial’s design, drug, disease and development history. We explain its forecast and compare it with clinical results and competing programs. The forecast is the chance of starting a Phase 3 trial within two years of primary completion—not the chance that this pain readout will be positive.
Trials behind the historical rate · 30 matched / 5 known outcomes
Model inputs, sensitivity and limitations
What moves this forecast?
Three key input groups that influence this prediction. Contributions describe model behavior, not causal effects.
How close are the comparison trials?
Model similarity and clinical relevance tell us different things.
What have the trials shown?
Four useful comparisons, each kept within its own study and analysis.
Explore all clinical evidence
Within-study comparison
Evidence register
What supports or challenges progression, the strength of each finding, and where it overlaps with the model.
Additional evidence is available but not displayed in this view. Download the full register for all findings. These directions are interpretations, not numerical probability adjustments.
Where would Halneuron fit?
Direct pain-treatment options first; adjacent sodium-channel evidence is labeled separately.
Explore the full landscape
| Program / developer | Mechanism | Setting & development | What it tells us |
|---|
Broader trial discovery cohort
These are registry search results, including prevention, non-drug and broader pain records. A registry endpoint is not an observed result.
| Registry / study | Intervention / conditions | Phase / status | Results posted |
|---|
Drug, trial and development details
Supporting evidence and practical questions for the upcoming readout.
Trial design, treatment and timeline
Mechanism, preclinical studies, human PK and safety
Standard of care and potential treatment position
What to check when topline results arrive
Ownership, financing, patents and scientific contributors
Sources
Clinical results come from original studies, registries and dated sponsor disclosures. Open a source for its review depth and exact location.